NovartisNVS stock threatened the lower boundary of its chase zone Tuesday after generics took a big bite out of Entresto, the heart-failure drug that accounts for 13% of the Swiss company's sales.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback